ATE291013T1 - Durch einen omega-thiarest substituierte phenyl- prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten - Google Patents

Durch einen omega-thiarest substituierte phenyl- prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten

Info

Publication number
ATE291013T1
ATE291013T1 AT99929831T AT99929831T ATE291013T1 AT E291013 T1 ATE291013 T1 AT E291013T1 AT 99929831 T AT99929831 T AT 99929831T AT 99929831 T AT99929831 T AT 99929831T AT E291013 T1 ATE291013 T1 AT E291013T1
Authority
AT
Austria
Prior art keywords
prostaglandin
omega
disease
syndrome
expected
Prior art date
Application number
AT99929831T
Other languages
English (en)
Inventor
Toru Maruyama
Shuichi Ohuchida
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE291013T1 publication Critical patent/ATE291013T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT99929831T 1998-07-15 1999-07-14 Durch einen omega-thiarest substituierte phenyl- prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten ATE291013T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20075298 1998-07-15
PCT/JP1999/003798 WO2000003980A1 (fr) 1998-07-15 1999-07-14 DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF

Publications (1)

Publication Number Publication Date
ATE291013T1 true ATE291013T1 (de) 2005-04-15

Family

ID=16429595

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99929831T ATE291013T1 (de) 1998-07-15 1999-07-14 Durch einen omega-thiarest substituierte phenyl- prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten

Country Status (21)

Country Link
US (1) US6462081B1 (de)
EP (1) EP1097922B1 (de)
JP (1) JP3174563B2 (de)
KR (1) KR100598660B1 (de)
CN (1) CN1173945C (de)
AT (1) ATE291013T1 (de)
AU (1) AU763668B2 (de)
BR (1) BR9912813B1 (de)
CA (1) CA2336952C (de)
DE (1) DE69924258T2 (de)
DK (1) DK1097922T3 (de)
ES (1) ES2239448T3 (de)
HU (1) HUP0204170A3 (de)
NO (1) NO327781B1 (de)
NZ (1) NZ509293A (de)
PT (1) PT1097922E (de)
RU (1) RU2220135C2 (de)
TR (1) TR200100623T2 (de)
TW (1) TWI249520B (de)
WO (1) WO2000003980A1 (de)
ZA (1) ZA200100295B (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE281432T1 (de) 1999-03-05 2004-11-15 Univ Duke C-16 ungesätigte fp-selektive prostaglandin analoge
CA2303060A1 (en) * 1999-04-14 2000-10-14 United States Gear Corporation Towed vehicle brake controller
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
AU7557600A (en) 1999-10-07 2001-05-10 Ono Pharmaceutical Co. Ltd. Erection insufficiency remedies
RU2259830C2 (ru) * 1999-11-24 2005-09-10 Оно Фармасьютикал Ко., Лтд. Фармацевтическая композиция для лечения заболеваний, связанных с потерей костной массы
TWI247606B (en) * 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
AU2227401A (en) * 2000-01-05 2001-07-16 Ono Pharmaceutical Co. Ltd. 5-thia-omega-(substituted phenyl)-prostaglandin e alcohols, process for preparing the alcohols and pharmaceutical preparations containing the same as the activeingredient
DE60120007T2 (de) * 2000-01-31 2006-11-16 Pfizer Products Inc., Groton Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US6586462B2 (en) * 2000-10-20 2003-07-01 Allergan, Inc. ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
GB0030541D0 (en) * 2000-12-14 2001-01-31 Glaxo Group Ltd Medical uses
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
RU2296122C2 (ru) * 2001-07-16 2007-03-27 Ф.Хоффманн-Ля Рош Аг Производные 2-пирролидона в качестве простаноидных агонистов и фармацевтическая композиция
NZ530885A (en) * 2001-07-23 2007-09-28 Ono Pharmaceutical Co Remedies for diseases with bone mass loss having EP4 agonist as the active ingredient
ES2360604T3 (es) * 2001-07-23 2011-06-07 Ono Pharmaceutical Co., Ltd. Remedios para enfermedades con pérdida de masa osea que tienen como ingrediente activo agonistas de ep4.
CN101284773A (zh) * 2001-08-09 2008-10-15 小野药品工业株式会社 羧酸衍生物及以它为活性成分的药剂
JP2003078830A (ja) * 2001-09-03 2003-03-14 Sony Corp デジタル放送受信装置および通信情報伝送方法
EP1467738A1 (de) * 2001-10-08 2004-10-20 Medical Research Council Verwendung von prostaglandin e synthase inhibitoren, oder ep2/ep4 rezeptor antagonisten, zur behandlung von uterine krankheiten
WO2003037373A1 (en) * 2001-10-31 2003-05-08 Medical Research Council Use of an ep2 or ep4 receptor antagonist and/or a cox-1 inhibitor for treating cervical cancer
JP2005511562A (ja) * 2001-10-31 2005-04-28 メディカル リサーチ カウンシル 月経困難症及び月経過多の治療のためのプロスタグランジンレセプターｅｐ２及び／又はｅｐ４のアンタゴニスト
JPWO2003041717A1 (ja) * 2001-11-12 2005-03-03 小野薬品工業株式会社 プロスタグランジン誘導体を有効成分とする局所投与用持続性フィルム状製剤
BR0308493A (pt) * 2002-03-18 2005-01-11 Pfizer Prod Inc Uso de agonistas de receptor seletivo de ep4 para o tratamento da insuficiência hepática, perda de permeabilidade do canal arterial, glaucoma ou hipertensão ocular
GB0208785D0 (en) * 2002-04-17 2002-05-29 Medical Res Council Treatment methtods
DE60334905D1 (de) * 2002-06-06 2010-12-23 Merck Frosst Canada Ltd 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
JP3678366B2 (ja) 2002-08-09 2005-08-03 大正製薬株式会社 止痒剤
US7737182B2 (en) 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
ES2584606T3 (es) 2002-10-10 2016-09-28 Ono Pharmaceutical Co., Ltd. Microesferas que comprenden ONO-1301
AU2003301900A1 (en) * 2002-11-13 2004-06-03 Fumie Sato Antipruritic drug
RU2335490C2 (ru) * 2003-02-07 2008-10-10 Оно Фармасьютикал Ко., Лтд. Соединения карбоновой кислоты, фармацевтическая композиция на их основе, способ лечения и применение
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
ATE394372T1 (de) 2003-03-03 2008-05-15 Serono Lab G-lactamderivate als prostaglandinagonisten
JP2006528154A (ja) 2003-07-18 2006-12-14 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ プロスタグランジン受容体のモジュレータとしてのヒドラジド誘導体
WO2005102389A2 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
EP1782830A4 (de) * 2004-08-10 2009-07-29 Ono Pharmaceutical Co Mittel zur prävention und/oder behandlung von erkrankungen der unteren harnwege mit ep4 agonist
US20080234337A1 (en) * 2004-08-10 2008-09-25 Ono Pharmaceutical Co., Ltd. Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist
JP2008518013A (ja) * 2004-10-26 2008-05-29 アラーガン、インコーポレイテッド プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
JPWO2006075690A1 (ja) * 2005-01-14 2008-06-12 小野薬品工業株式会社 安定な医薬組成物
KR20080000647A (ko) 2005-04-28 2008-01-02 오노 야꾸힝 고교 가부시키가이샤 경피 흡수 제제
GB0524103D0 (en) 2005-11-26 2006-01-04 Medical Res Council Healing
US7511168B2 (en) * 2006-01-18 2009-03-31 Shih-Yi Wei Processes and intermediates for the preparations of prostaglandins
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
US8410171B2 (en) 2006-10-26 2013-04-02 Ono Pharmaceutical Co., Ltd. Adhesive preparation
AU2007331471C1 (en) 2006-12-15 2013-07-25 Glaxo Group Limited Benzamide derivatives as EP4 receptor agonists
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
AU2008246579A1 (en) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
CA2739571A1 (en) 2008-10-29 2010-08-26 Aerie Pharmaceuticals, Inc. Amino acid salts of prostaglandins
KR101172638B1 (ko) 2008-12-30 2012-08-08 조선대학교산학협력단 신규한 티아졸리딘디온 유도체 및 그의 용도
EP3828172A1 (de) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Hemmer mit doppelmechanismus zur behandlung von erkrankungen
US20120136011A1 (en) * 2010-07-30 2012-05-31 Allergan, Inc. Compounds and methods for skin repair
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
AU2012217630A1 (en) 2011-02-17 2013-09-05 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2678022A2 (de) 2011-02-23 2014-01-01 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
EP2814526B1 (de) 2012-02-16 2016-11-02 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
WO2013123270A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123275A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123272A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
US20150126573A1 (en) 2012-05-09 2015-05-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
CN107802623B (zh) 2012-07-19 2020-10-30 开曼化学股份有限公司 用于ep4介导的骨相关疾病和病症的二氟内酰胺组合物
EP2913047B1 (de) 2012-10-29 2019-05-08 Cardio Incorporated Spezifisches therapeutikum für pulmonale erkrankungen
ES2852377T3 (es) 2013-03-15 2021-09-13 Aerie Pharmaceuticals Inc Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
JP2016527006A (ja) 2013-07-19 2016-09-08 ケイマン ケミカル カンパニー， インコーポレーテッド 骨成長を促進するための方法、システム、及び組成物
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
KR102568079B1 (ko) 2016-08-31 2023-08-17 에어리 파마슈티컬즈, 인코포레이티드 안과용 조성물
AU2018243687C1 (en) 2017-03-31 2020-12-24 Alcon Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CA3112391A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58198466A (ja) 1982-05-12 1983-11-18 Teijin Ltd ５−チアプロスタグランジン類およびその製造法
JPH072711B2 (ja) 1986-09-24 1995-01-18 帝人株式会社 プロスタグランジンｅ▲下１▼誘導体の製造法
EP0386901A1 (de) * 1989-02-20 1990-09-12 Ono Pharmaceutical Co., Ltd. 5-Hetero-6-oxo-PGE-Derivate
JPH03223244A (ja) * 1989-02-20 1991-10-02 Ono Pharmaceut Co Ltd ５―ヘテロ―６―オキソ―ｐｇｅ誘導体、それらの製造方法およびそれらを含有する薬剤
JP3579448B2 (ja) 1993-12-29 2004-10-20 大正製薬株式会社 プロスタグランジン誘導体、その塩およびその使用

Also Published As

Publication number Publication date
US6462081B1 (en) 2002-10-08
NO20010213L (no) 2001-03-15
DE69924258D1 (de) 2005-04-21
AU4651899A (en) 2000-02-07
JP3174563B2 (ja) 2001-06-11
NO327781B1 (no) 2009-09-21
PT1097922E (pt) 2005-06-30
EP1097922A1 (de) 2001-05-09
NO20010213D0 (no) 2001-01-12
ES2239448T3 (es) 2005-09-16
HUP0204170A2 (hu) 2003-04-28
TWI249520B (en) 2006-02-21
WO2000003980A1 (fr) 2000-01-27
EP1097922A4 (de) 2003-02-12
EP1097922B1 (de) 2005-03-16
AU763668B2 (en) 2003-07-31
KR20010053386A (ko) 2001-06-25
DK1097922T3 (da) 2005-05-30
CN1312796A (zh) 2001-09-12
CA2336952C (en) 2009-09-15
DE69924258T2 (de) 2006-01-26
CA2336952A1 (en) 2000-01-27
NZ509293A (en) 2003-05-30
BR9912813A (pt) 2001-05-02
CN1173945C (zh) 2004-11-03
RU2220135C2 (ru) 2003-12-27
HUP0204170A3 (en) 2005-03-29
KR100598660B1 (ko) 2006-07-13
TR200100623T2 (tr) 2001-06-21
ZA200100295B (en) 2002-07-10
BR9912813B1 (pt) 2010-11-30

Similar Documents

Publication Publication Date Title
ATE291013T1 (de) Durch einen omega-thiarest substituierte phenyl- prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten
MXPA05006989A (es) Derivados de diamina.
NL300006I2 (nl) Imidazolylalkeenzuurderivaten.
KR970704435A (ko) 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands)
DE69818286D1 (de) Pyridylverbindungen und diese enthaltende pharmazeutische zubereitungen
HU9401415D0 (en) Enzofuranyl- and -thiophenyl-alkane-carboxylic acid derivatives, pharmaceutical compositions contaning them, and process for producing them
RU2004126950A (ru) Использование выделяющих co соединений при изготовлении лекарственного средства для лечения воспалительных заболеваний
EP2269610A3 (de) Heterozyklische Derivate und ihre Verwendung als Stearoyl-Coa-Desaturase-Inhibitoren
TR200402656T4 (tr) Antikanser ajanları olarak faydalı tiyofen türevleri
DE60126947D1 (de) Behandlung der glykogenspeicherkrankheit typ ii
DE59208974D1 (de) Neue pyrazinderivative, ihre herstellung und verwendung
FR2874016B1 (fr) Nanoparticules de derives de la gemcitabine
DE60220255T2 (de) N-phenylarylsulfonamidverbindung, arzneimittel, das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung
JPS6217994B2 (de)
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
DE69109592T2 (de) Pyrazoloquinolinderivate.
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
IT1265077B1 (it) Derivati del cicloeptimmidazolo, metodo per la loro produzione e agenti terapeutici contenenti questi composti
WO2001082858A2 (de) Neue verbindungen zur behandlung inflammatorischer und kardiovaskulärer erkrankungen
ES2247060T3 (es) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial.
HUP9601526A2 (hu) Véralvadásgátló hatású peptidil-arginin-aldehid-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
ATE151770T1 (de) Cephalosporinverbindungen und deren herstellung
KR890009890A (ko) 하이드록시 피리미딘의 아실 유도체
CH644108A5 (en) Anti-inflammatory imidazoles and processes for their preparation
ATE1598T1 (de) 5(10- 9)abeo-ergolin-derivate, ihre herstellung und sie enthaltende therapeutische zusammensetzungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1097922

Country of ref document: EP